Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound (tirzepatide) provided a 47% greater relative weight loss vs. to Wegovy (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% vs. 13.7% with Wegovy.
At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least one weight-related medical problem and without diabetes.
SURMOUNT-5 was a multi-centre, randomised, open-label, phase 3b trial evaluating the efficacy and safety of Zepbound compared with Wegovy in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease, who did not have diabetes.
The trial randomised 751 participants across the US and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of Zepbound (10mg or 15mg) or Wegovy (1.7mg or 2.4mg). The primary objective of the study was to demonstrate Zepbound's superiority in percent change from baseline in body weight at 72 weeks compared to Wegovy.
"Given the increased interest around obesity medications, we conducted this study to help health care providers and patients make informed decisions about treatment choice," said Dr Leonard C Glass, senior vice president of global medical affairs at Lilly Cardiometabolic Health. "We are thrilled that today's findings showed the superior weight loss of Zepbound, which helped patients achieve 47% more relative weight loss compared to Wegovy. Zepbound is in a class of its own as the only FDA-approved dual GIP and GLP-1 receptor agonist obesity medication, and it's changing how millions of people manage this chronic disease."
In addition, in a key secondary endpoint, 31.6% of people taking Zepbound achieved at least 25% body weight loss, compared to 16.1% of those taking Wegovy.
The overall safety profile of Zepbound in SURMOUNT-5 was similar to previously reported SURMOUNT trials. The most commonly reported adverse events in SURMOUNT-5 for both Zepbound and Wegovy were gastrointestinal-related and were generally mild to moderate in severity.
Lilly will continue to evaluate the SURMOUNT-5 results, which will be published in a peer-reviewed journal and presented at a medical meeting next year.
Comments